Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2/3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Plasma cell 1Genitourinary 1

Conditions

Nephrotic Syndrome 1Neoplasm Metastasis 1Kidney Diseases 1Gastrointestinal Diseases 1Familial Mediterranean Fever 1Arthritis, Rheumatoid 1Amyloidosis 1

Interventions

Dexamethasone 8daratumumab 5Lenalidomide 5Bortezomib 5Trimethoprim, Sulfamethoxazole Drug Combination 4Thalidomide 4Cyclophosphamide 4gamma-Globulins 3Ciprofloxacin 3carfilzomib 2Melphalan 2Immunoglobulins, Intravenous 2Calcium Dobesilate 2Amoxicillin-Potassium Clavulanate Combination 2trametinib 1tanespimycin 1pomalidomide 1pazopanib 1fludarabine 1dabrafenib 1cobimetinib 1Whole-Body Irradiation 1Vemurafenib 1Stem Cell Transplantation 1Rivaroxaban 1Radiotherapy 1Radiation 1Pharmaceutical Preparations 1Mesna 1MAGEA3 protein, human 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Pharmaceutical Preparations × Plasma cell × Clear all
NCT00035334 2006-02-14

Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis

Bellus Health Inc. - a GSK company

Phase 2/3 Completed
150 enrolled
GastrointestinalGenitourinaryPlasma cell

Amyloidosis, Arthritis, Rheumatoid, Gastrointestinal Diseases, Kidney Diseases, Neoplasm Metastasis, Nephrotic Syndrome, Familial Mediterranean Fever

Data powered by HemOnc (CC BY 4.0) Colophon âš¡